Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Safety analyses from the phase III EMBER-3 trial
- Joyce O’Shaughnessy
- , Francois Clement Bidard
- , Patrick Neven
- , Monica Lis Casalnuovo
- , Philippe Georges Aftimos
- , Cristina Saura Manich
- , Nadia Harbeck
- , Lisa A. Carey
- , Giuseppe Curigliano
- , Jose A. García-Sáenz
- , María Fernández-Abad
- , Larissa Carvalho Lopes De Paula
- , Yeon Hee Park
- , Ozgur Ozyilkan
- , Maria Munoz
- , Sabrina Formentini
- , Emily Barrett
- , Shanshan Cao
- , Aarti Chawla
- , Komal L. Jhaveri
- Baylor Health Care System
- Sarah Cannon Research Institute
- Université Paris-Saclay
- KU Leuven
- Hospital Maria Curie
- Université libre de Bruxelles
- Vall d’Hebron University Hospital
- Ludwig Maximilian University of Munich
- University of North Carolina at Chapel Hill
- University of Milan
- Hospital Clínico San Carlos de Madrid
- Hospital Ramon y Cajal
- Instituto Brasileiro de Controle do Câncer
- Baskent University
- Eli Lilly
- Memorial Sloan-Kettering Cancer Center
Research output: Contribution to journal › Article › peer-review
1
Link opens in a new tab
Scopus
citations